CD4+ regulatory T (Treg) cells play a critical role in autoimmune diseases by suppressing the CD4+ and CD8+ effector cell responses, but inhibit immune responses needed for effective cancer immunotherapy. We recently demonstrated the presence of antigen-specific CD4+ Treg cells in melanoma and prostate tumor-infiltrating T cells. These observations may explain, at least in part, why attempts to elicit strong and durable antitumor responses with cancer vaccines (comprising MHC class l-restricted tumor antigens or peptides) have been largely unsuccessful. The goals of this project are to investigate whether the presence of Treg cells in prostate cancer cause immune suppression and tolerance, and whether antitumor immunity can be enhanced by reversing the suppressive function of Treg cells. Research in the applicant's laboratory has established over 50 prostate tumor infiltrating T cells (PTILs). Both CD4+ and CD8+ Treg cells from several PTILs showed antigen specificity and potent suppressive activity. More importantly, we recently demonstrated that the suppressive function melanoma-derived Treg cells could be specifically reversed by TLR ligands. These preliminary studies prompted us to test our hypothesis that the suppressive function of prostate cancer-derived CD4+ and CD8+ Treg cells could be regulated or reversed by cytokines and TLR signaling. These unique prostate Treg cells lines, together with several newly developed technologies, should enable identification of important ligands for CD4+ and CD8+ Treg cells, permitting in turn more rigorous testing of a novel concept - that reversing the suppressive function of CD4+ and/or CD8+ Treg cells may boost the effectiveness of cancer immunotherapy. To test our novel concept and hypothesis, we propose three specific research aims: (1) characterize different subsets of PTILs on the basis of phenotypic markers, cytokine profiles and suppressive mechanisms; (2) use established CD4+ Treg cell lines/clones to identify genes encoding the ligands of these cells and then characterize their roles in regulating the activation of Treg cells; (3) dissect the immunosuppressive mechanisms and regulation of Treg cells by TLR signaling to gain critical information needed to test our hypothesis that reversing the suppressive function of CD4+ Treg cells would enhance antitumor immunity in vivo. The strategies emerging from this 5-year proposal will be applied to the regulation of Treg cell function in different human tumors to verify that a shift in the CD4+ Treg/effector cell balance through TLR signaling or cytokines is indeed conducive to more effective cancer immunotherapy. A positive outcome of these studies would open new opportunities for treating cancer patients and perhaps infectious and autoimmune diseases as well. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA121191-01
Application #
7087614
Study Section
Transplantation, Tolerance, and Tumor Immunology (TTT)
Program Officer
Mccarthy, Susan A
Project Start
2006-08-07
Project End
2011-07-31
Budget Start
2006-08-07
Budget End
2007-07-31
Support Year
1
Fiscal Year
2006
Total Cost
$266,250
Indirect Cost
Name
Baylor College of Medicine
Department
Genetics
Type
Schools of Medicine
DUNS #
051113330
City
Houston
State
TX
Country
United States
Zip Code
77030
Jin, Shouheng; Tian, Shuo; Chen, Yamei et al. (2016) USP19 modulates autophagy and antiviral immune responses by deubiquitinating Beclin-1. EMBO J 35:866-80
Qin, Yunfei; Liu, Qingxiang; Tian, Shuo et al. (2016) TRIM9 short isoform preferentially promotes DNA and RNA virus-induced production of type I interferon by recruiting GSK3? to TBK1. Cell Res 26:613-28
Yang, Zhifen; Xian, Huifang; Hu, Jiajia et al. (2015) USP18 negatively regulates NF-?B signaling by targeting TAK1 and NEMO for deubiquitination through distinct mechanisms. Sci Rep 5:12738
Cui, Jun; Song, Yanxia; Li, Yinyin et al. (2014) USP3 inhibits type I interferon signaling by deubiquitinating RIG-I-like receptors. Cell Res 24:400-16
Li, Qingtian; Wang, Helen Y; Chepelev, Iouri et al. (2014) Stage-dependent and locus-specific role of histone demethylase Jumonji D3 (JMJD3) in the embryonic stages of lung development. PLoS Genet 10:e1004524
Sonpavde, Guru; Wang, Mingjun; Peterson, Leif E et al. (2014) HLA-restricted NY-ESO-1 peptide immunotherapy for metastatic castration resistant prostate cancer. Invest New Drugs 32:235-242
Deng, Tuo; Lyon, Christopher J; Minze, Laurie J et al. (2013) Class II major histocompatibility complex plays an essential role in obesity-induced adipose inflammation. Cell Metab 17:411-22
Zhao, Wei; Li, Qingtian; Ayers, Stephen et al. (2013) Jmjd3 inhibits reprogramming by upregulating expression of INK4a/Arf and targeting PHF20 for ubiquitination. Cell 152:1037-50
Ajibade, Adebusola A; Wang, Helen Y; Wang, Rong-Fu (2013) Cell type-specific function of TAK1 in innate immune signaling. Trends Immunol 34:307-16
Ajibade, Adebusola Alagbala; Wang, Qinfu; Cui, Jun et al. (2012) TAK1 negatively regulates NF-?B and p38 MAP kinase activation in Gr-1+CD11b+ neutrophils. Immunity 36:43-54

Showing the most recent 10 out of 16 publications